Flex sends out an SOS signal, scrapping studies and slashing staff as it hunts a survival strategy — shares crater
Flex Pharma today said that its lead drug has a big problem that is forcing the little biotech to scrap mid-stage studies and hunker down …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
